Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | August 28, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,624 |
Reported balance
After 2026-08-28 transaction · row 1
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 5,000 · Balance 11,624 F1: Restricted stock unit award that vests on 03/01/2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/01/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 1, 2026 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000267 · wk-form4_1788295172.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,624 F1 · shares: Restricted stock unit award that vests on 03/01/2029. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 357 | $483.36 | $172,559.52 |
DisclosureSEC source: 0000875320-26-000125 · wk-form4_1772485797.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,624 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 22:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 223 | $486.35 | $108,456.05 |
DisclosureSEC source: 0000875320-26-000104 · wk-form4_1772146579.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,981 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 546 | $485.11 | $264,870.06 |
DisclosureSEC source: 0000875320-26-000104 · wk-form4_1772146579.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,204 Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 638 | $473.68 | $302,207.84 |
DisclosureSEC source: 0000875320-26-000080 · wk-form4_1771535003.xml · nonDerivative · entry 4 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,750 F2 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,557 | $489.46 | $762,089.22 |
DisclosureSEC source: 0000875320-26-000080 · wk-form4_1771535003.xml · nonDerivative · entry 3 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,388 F2 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 598 | $483.75 | $289,282.50 |
DisclosureSEC source: 0000875320-26-000080 · wk-form4_1771535003.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,945 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,809 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000080 · wk-form4_1771535003.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,543 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,393 | $487.76 | $679,449.68 |
DisclosureSEC source: 0000875320-26-000058 · wk-form4_1771449464.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,734 Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,376 | $460.43 | $633,551.68 |
DisclosureSEC source: 0000875320-26-000036 · wk-form4_1770932861.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,127 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 592 | $468.41 | $277,298.72 |
DisclosureSEC source: 0000875320-26-000036 · wk-form4_1770932861.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,503 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001856587-26-000002 · wk-form4_1769461964.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,095 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001856587-26-000002 · wk-form4_1769461964.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,795 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,241 | $479.61 | $595,196.01 |
DisclosureSEC source: 0000875320-25-000122 · wk-form4_1740777887.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,845 Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 884 | $480.95 | $425,159.80 |
DisclosureSEC source: 0000875320-25-000103 · wk-form4_1740603976.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,086 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 828 | $483.28 | $400,155.84 |
DisclosureSEC source: 0000875320-25-000103 · wk-form4_1740603976.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,970 Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 671 | $455.06 | $305,345.26 |
DisclosureSEC source: 0000875320-25-000079 · wk-form4_1740000082.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,798 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 564 | $463.46 | $261,391.44 |
DisclosureSEC source: 0000875320-25-000079 · wk-form4_1740000082.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,469 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000057 · wk-form4_1739567081.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,033 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,376 | $459.83 | $632,726.08 |
DisclosureSEC source: 0000875320-25-000033 · wk-form4_1739395442.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,953 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2024. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 591 | $467.98 | $276,576.18 |
DisclosureSEC source: 0000875320-25-000033 · wk-form4_1739395442.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,329 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,854 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000007 · wk-form4_1738876523.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,920 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000007 · wk-form4_1738876523.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,066 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $419.00 | $100,560.00 |
DisclosureSEC source: 0000875320-24-000113 · wk-form4_1712174533.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 225 | $418.10 | $94,072.50 |
DisclosureSEC source: 0000875320-24-000113 · wk-form4_1712174533.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,740 Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 883 | $425.70 | $375,893.10 |
DisclosureSEC source: 0000875320-24-000097 · wk-form4_1709069345.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,965 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 828 | $431.79 | $357,522.12 |
DisclosureSEC source: 0000875320-24-000097 · wk-form4_1709069345.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,848 Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,374 | $420.24 | $577,409.76 |
DisclosureSEC source: 0000875320-24-000041 · wk-form4_1707860917.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,676 F1 · kind: Transaction made pursuant to Ms.Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 591 | $422.74 | $249,839.34 |
DisclosureSEC source: 0000875320-24-000041 · wk-form4_1707860917.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,050 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,853 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000016 · wk-form4_1707427226.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,641 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000016 · wk-form4_1707427226.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,788 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 289 | $329.82 | $95,317.98 |
DisclosureSEC source: 0001209191-23-033312 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,838 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 176 | $313.74 | $55,218.24 |
DisclosureSEC source: 0001209191-23-022689 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,127 Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 42 | $289.63 | $12,164.46 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 4 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,303 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 183 | $288.68 | $52,828.44 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 3 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,345 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.68 (range $288.24 to $289.17). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 982 | $287.25 | $282,079.50 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.25 (range $286.79 to $287.71). Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 502 | $289.12 | $145,138.24 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,510 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006879 · doc4.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,012 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006879 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,062 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 104 | $271.68 | $28,254.72 |
DisclosureSEC source: 0000899243-22-015762 · doc4.xml · nonDerivative · entry 4 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,496 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $271.68 (range $271.25 to $272.23). Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 83 | $269.51 | $22,369.33 |
DisclosureSEC source: 0000899243-22-015762 · doc4.xml · nonDerivative · entry 3 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $269.51 (range $269.12 to $269.90). Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 80 | $268.46 | $21,476.80 |
DisclosureSEC source: 0000899243-22-015762 · doc4.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,683 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $268.46 (range $268.05 to $268.86). Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 60 | $267.37 | $16,042.20 |
DisclosureSEC source: 0000899243-22-015762 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,763 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $267.37 (range $266.86 to $267.85). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 137 | $263.09 | $36,043.33 |
DisclosureSEC source: 0000899243-22-013713 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,823 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006761 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,960 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.